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Abstract: The potential antiplatelet aggregation effects of mango pulp and its by-products (peel, husk
seed, and seed) due to the presence of bioactive compounds were explored. Among them, mango seed
exhibited a 72% percentage inhibition of platelet aggregation induced by adenosine 5’-diphosphate
(ADP) agonist with a demonstrated dose-dependent effect. This biological feature could be caused by
the chemical differences in phenolic composition. Mango seed was especially rich in monogalloyl
compounds, tetra- and penta-galloylglucose, ellagic acid, mangiferin, and benzophenones such
as maclurin derivatives and iriflophenone glucoside. Mangiferin showed an inhibitory effect of
31%, suggesting its key role as one of the main contributors to the antiplatelet activity of mango
seed. Therefore, mango seed could be postulated as a natural source of bioactive compounds with
antiplatelet properties to design functional foods or complementary therapeutic treatments.
Keywords: Mango; by-products; antiplatelet activity; bioactive compounds; HPLC-DAD-q-TOF-MS
1. Introduction
Cardiovascular diseases (CVD) have the highest mortality rate of all types of diseases worldwide.
Atherosclerosis and thrombotic processes associated with the rupture of vulnerable plaques are the
main triggers of cardiovascular and cerebrovascular strokes [1,2]. It has been determined that platelets
represent the bridge between inflammation and thrombosis, which are fundamental processes in the
development of atherothrombosis [3]. The general pathogenies entails platelet activation, subsequent
adhesion, release of granule content, and platelet aggregation [4]. The multiple mechanisms of
action and the side effects of drugs make the research on natural bioactive compounds useful for
pharmaceutical constituents in the prevention or complementary treatment of antiplatelet therapy.
The antiplatelet activity of numerous bioactive compounds detected in fruits and vegetables and
their multiple mechanisms of actions have recently been highlighted [5]. However, these bioactive
compounds can not only be found in the edible fraction but also in their by-products. This fact has
made by-products a profitable niche of phytochemicals to be used as functional substances [6], although
some of their characteristics such as bioavailability, pharmakinetic, pharmacodynamics properties,
safety, and toxicity still remain unclear.
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In this context, mango fruit (Mangifera indica L) is the crop with the second highest production
and acreage requirements, behind only bananas [7]. Although it is mainly consumed fresh, plenty
of mango-derived products have been created such as juice, nectar, purée, ice cream, jam, canned
slices, chutneys, etc. Consequently, by-products such as peel, seed, and seed husk, constituting
35%–60% of the fruit [8], are generated during the industrial processes. Recently, the high content of
health-enhancing compounds like polyphenols, anthocyanins, and carotenoids in mango by-products
has been reported [9]. Thus, different scientific investigations have been focused on the revalorization
of mango by-products due to their functional properties and potential therapeutic uses of their bioactive
compounds [10,11].
Recently, the antioxidant and anti-inflammatory effects of phenolic compounds obtained from
mango by-products and water extracts by reducing the nitric oxide (NO) levels produced by
lipopolysaccharides (LPS)-stimulated macrophages have been reported [12]. This biological activity
postulates mango by-products to enhance cardiovascular health, and makes other physiological effects
of mango by-products plausible against the pathogenies of cardiovascular diseases.
Therefore, the main goal of this work is to explore the inhibitory effects of platelet aggregation
of extracts from mango pulp and its by-products (peel, husk seed, and seed) and characterize the
phenolic composition in order to figure out the compounds responsible for the antiplatelet activity.
2. Materials and Methods
2.1. Fruit Material and Sample Preparation
About 20 kg of Keitt mangos cultivated in the Tropical Coast of Granada were provided by
Miguel García Sanchez e Hijos S.A. (Motril, Spain) at the optimum maturation stage (13.1–16.0 ◦Brix)
in November 2016. Once they had arrived at the laboratory, samples were cleaned and the different
parts of mango (pulp, peel, seed, and seed husk) were separated manually and cut into small and
homogenous pieces. To preserve chemical composition of mango pulp and its by-products, samples
were submitted to a lyophilization process (Advantage Plus EL-85 freeze dryer, SP Scientific, Ipswich,
Suffolk, UK). Then each sample was milled (IKA M20-IKAWERKE GmbH & Co. KG, Staufen, Germany),
homogenized, and stored at −18 ◦C prior to their analyses.
2.2. Isolation of Extracts Rich in Polyphenols from Mango and its By-Produts
2.2.1. Extracts for Anti-Platelet Aggregation Activity Assay
The isolation of polyphenols from samples was carried out following an adapted method from
Gómez-Caravaca et al., 2016 [13]. For each sample, 2 g of freeze-dried powder were sonicated for 15 min
with 40 mL of a solution of methanol/water (80:20 v/v). After the extraction process, the mixture was
centrifuged for 15 min at 7700 g and at 4 ◦C. The supernatant was removed and other two consecutive
extraction steps were repeated. All supernatants were collected, evaporated to dryness, and stored at
−18 ◦C. With the aim of obtaining arond 2 g of each extract, we performed the antiplatelet activity and
took into account the yield of each extraction (pulp, 79.4%; peel, 44.6%; seed husk, 7.4%, and husk,
16.7%). In total, 4 g of pulp, 6 g of peel, 32 g of seed husk, and 16 g of husk were processed using the
previous extraction procedure.
2.2.2. Extracts for Analytical Characterization
For each samples (pulp, peel, seed husk, and seed) 0.5 g of freeze-dried powder were extracted
with 10 mL of methanol/water (80:20 v/v) under sonication for 15 min [13]. After the extraction process,
mixture was centrifuged for 15 min at 7700 g and at 4 ◦C. The supernatant was removed and the
extraction step was then repeated twice. Finally, all supernatants were also collected, evaporated,
reconstituted in 3 mL of methanol/water (80:20 v/v), filtered (0.2 µM, Milllipore), and stored at −18 ◦C.
All extractions were performed in duplicate.
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2.3. Human Platelet Isolation
Platelet-rich plasma (PRP) was obtained from six healthy young volunteers who had previously
signed a consent report. Samples were extracted by phlebotomy in 3.2% sodium citrate tubes (Becton
Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Then, blood samples were centrifuged
(DCS-16 Centrifugal Presvac RV) at 240 g for 10 min to obtain platelet-rich plasma (PRP). Two-thirds of
PRP was removed and centrifuged at 650 g for 10 min. The platelet count was performed in a blood
count (Bayer Advia 60 Hematology System, Tarrytown, NY, USA).
2.4. Anti-Platelet Aggregation Activity Assay
The anti-platelet aggregation activity of mango and its by-products was evaluated by a
turbidimetric method [14] using a lumi-aggregometer (Chrono-Log, Haverton, PA, USA). The PRP
(200 × 109 platelets/L) was preincubated with 20µL of phosphate-buffered saline, PBS, (negative control:
maximum aggregation), or power extracts from each part of the mango (1 mg/mL) for 3 min at 37 ◦C.
In order to evaluate the dose-dependent effects against platelet aggregation, different concentrations
(0.1, 0.5, and 1 mg/mL) of the more active extract were tested as well as the antiplatelet properties of
some standards compounds such as mangiferin (Sigma-Aldrich, St. Louis, Missouri, MO, USA) at
1 mg/mL. For all assays, platelet aggregation was induced by adding adenosine 5’-diphosphate (ADP,
4 µM) supplied by Sigma-Aldrich (St. Louis, Missouri, MO, USA) as an agonist. Platelet aggregation
was measured by triplicate as the increase in light transmission occurred for 6 min and results were
expressed as a percentage of inhibition of aggregation.
2.5. Phenolic Characterization of Extracts by HPLC-DAD-q-TOF-MS
Power extracts from the extraction of 0.5 g of samples were redissolved in 3 mL of methanol/water
(80:20 v/v). After their filtration, extracts were analyzed by HPLC-DAD-q-TOF-MS (Agilent 1200
series coupled to 6540 Agilent Ultra-High-Definition Accurate-Mass q-TOF-MS, Agilent Technologies,
Palo Alto, CA, USA) according to the method proposed by Gómez-Caravaca et al. [13].
Identification was performed based on relative retention times, UV-Vis spectra, and mass spectra
obtained by q-TOF-MS and from the literature. Quantification was carried out using calibration
standards curves of gallic acid, coumaric acid, ferulic acid, vanillic acid, catechin, quercetin, ellagic
acid, and mangiferin (Sigma Aldrich, St. Louis, MO, USA). Spectral and chromatographic data are
compliled in Supplementary Table S1. Integration and data processing were performed using Mass
Hunter Workstation Software, Qualitative Analysis, version B.07.00 (Agilent Technologies, Inc. 2014).
2.6. Statistical Analysis
The IBM SPSS statistics v.22.0 for Windows statistical package was employed to carry out statistical
analysis. Anti-platelet aggregation data set was submitted to the ANOVA analysis and the Tukey’s
post-hoc test, while the Student-Newman-Keuls test was applied to the chemical data in order to
determine the significant differences between samples.
3. Results and Discussion
3.1. Anti-Platelet Aggregation Activity of Mango and its By-Products
The anti-platelet aggregation activity of extracts from edible part of mango (pulp) and its
by-products (peel, seed husk, and seed) was evaluated on a human platelet whose aggregation was
induced by using ADP (4 µM) as an agonist. Inhibition percentages of platelet aggregation of extracts
from mango and its by-products under the optimum maturation stage at a concentration of 1.0 mg/mL
are shown in Figure 1. It can be observed that human platelet aggregation triggered by the ADP
agonist was not significantly inhibited by pulp, skin, and husk seed extracts compared to the negative
control. However, mango seed extract exhibited a significantly higher inhibition percentage, which
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was around 72%. These findings can hardly be compared with others due to the scarce bibliography
regarding the antiplatelet activity of mango by-products. Recently, the influence of the ripening stage
of mango peel on rat platelet aggregation has been reported [15]. Ripe fruit peel extract showed better
platelet aggregation inhibitory effects. The inhibition percentage observed in ripened mango peel
water extract at 0.8 mg/mL in rat platelets was considerably higher (approximately 25%) in comparison
with our results tested against human platelet (approximately 10%). To the best of our knowledge,
anti-platelet aggregation data on mango pulp and their by-products on human blood have not been
reported until now.
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Figure 1. Antiplatelet aggregation activity results of extracts from mango and its by-products (peel,
seed husk and seed) at 1.0 mg/mL against adenosine 5’-diphosphate (ADP) agonist (4 µM) expressed
as mean value of inhibition percentages (n = 6). Data was analyzed using ANOVA of one factor.
Post hoc analyses were conducted using Tukey’s test. *** denotes significant differences compared to
the negative control (absence of extract) at p = 0.001; ns denotes no statistical differences.
Therefore, based our results, mango seed extract was shown to be a potential inhibitor of human
platelet aggregation induced by ADP agonist at 1.0 mg/mL with an inhibition percentage of 72%.
The current study also examined the dose-dependent effects of mango seed extract on inhibition of
platelet aggregation. To investigate the dose-dependent activity, several concentrations of mango
seed extract (1.0, 0.5 and 0.1 mg/mL) were tested against the platelet aggregation induced by ADP
agonist (4 µM). Significant differences in antiplatelet aggregation activity were identified between the
highest mango seed extract (1.0 mg/mL) and the middle dose (0.5 mg/mL) at p = 0.001 and p = 0.01,
respectively (Figure 2). Meanwhile no significant differences were found among the negative control
and the lowest dose tested (0.1 mg/mL). Therefore, data showed a clear dose-dependent effect that
increased the inhibition of platelet aggregation when the mango seed extract concentration increased.
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Figure 2. Study of the dose-dependent effect of mango seed extract on antiplatelet aggregation activity
against ADP agonist (4 µM) expressed as a mean value of inhibition percentages (n = 6). Data were
analyzed using ANOVA of one factor. Post hoc analyses were conducted by Tukey’s test, ** and ***
denotes significant differences at p = 0.01 and p = 0.001, respectively; ns denotes no statistical differences.
3.2. Phenolic Characterization of Extracts by HPLC-DAD-q-TOF-MS
The nutraceutical and pharmaceutical significance of mango to human health has been attributable
to its phenolic composition [11]. Therefore, a phenolic characterization of the edible and non-edible
parts of mango was carried out with the aim to relate chemical differences with the antiplatelet
activity observed by mango seed. A large number of phenolic compounds with different natures and
structures were detected in mango pulp and its by-products. The most abundant and numerous family
found in mango was gallic acid derivatives (Table 1). The characteristic high content of gallic acid of
mango fruit and its by-products in comparison with other tropical fruits has already been determined
previously [12,16].
Mango seed was particularly rich in monogalloyl compounds compared to the rest of mango
parts, especially edible mango fraction and seed husk by-product. The sum of the total monogalloyl
compounds reached the value of 720.30± 2.27 mg/100 gdry matter in mango seed. In contrast, considerable
lower concentrations of total monogalloyl compounds were found in pulp, peel, and seed husk
(52.18 ± 0.10, 235.34 ± 11.07, and 68.15 ± 3.48 mg/100 gdry matter, respectively). It was noteworthy that
the highest content of methylgallate was observed in mango seed (558.86 ± 6.74 mg/100 gdry matter),
which was the major phenolic compound detected in this matrix. The strong antioxidant power of this
compound has already been reported in the bibliogra hy [10]. Significantly higher concentrations
of other monogalloyl compounds such as gallic acid, galloyl diglucoside, and galloylquinic acid in
mango seed were also found. Higher quantities of galloylglucose were found in mango peel, as were
monogalloyl derivatives. On the other hand, both edible mango fraction and seed husk exhibited the
lowest values of monogalloyl compounds compared to peel and seed by-products. These findings
were in good agreement with those reported by other authors, who also detected higher concentrations
of gallic acid and methylgallate in mango seed and found more abundant galloylglucose in mango
peel [13].
Structurally, gallic acid contains hydroxyl groups and a carboxylic acid group, so its molecules have
the abilit to react with one another to generate digalloyl compounds. Regarding these compounds,
a contrary behavior was evidenced since the highest concentrations of digalloylglucose, methyldigallate,
and digalloylquinic acid were found in mango peel (Table 1). Consequently, peel was found to be the
fraction of mango with the greatest digalloyl content (137.98 ± 4.09 mg/100 gdry matter) in comparison
with the rest of samples whose composition on digalloyl compounds ranged between 8.13 and
22.50 mg/100 gdry matter).
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Table 1. Mean concentration of gallic acid derivative compounds from different parts of Keitt mango
variety at optimum maturation stage expressed as mg/100 gdry matter.
COMPOUNDS
PULP PEEL SEED HUSK SEED
MEAN SD MEAN SD MEAN SD MEAN SD
Monogalloyl compounds
Gallic acid 1.55 ± 0.02 a 3.57 ± 0.47 b 3.93 ± 0.24 b 16.67 ± 0.03 c
Galloylglucose 42.36 ± 0.23 a 112.17 ± 1.10 c 43.09 ± 1.83 a 53.67 ± 4.73 b
Galloyl diglucoside 0.09 ± 0.00 a 5.69 ± 0.07 b 0.25 ± 0.01a 6.64 ± 0.11 c
Methylgallate 5.41 ± 0.48 a 54.14 ± 7.77 b 14.43 ± 0.89 a 558.86 ± 6.74 c
Galloylquinic acid 2.76 ± 0.12 a 59.77 ± 1.79 c 6.45 ± 0.50 b 84.46 ± 0.34 d
Digalloyl compounds
Digallic acid ND 2.54 ± 0.34 a 1.67 ± 0.00 a 3.64 ± 0.57 b
Digalloylglucose 4.59 ± 0.03 a 31.17 ± 0.57 c 9.18 ± 0.59 b 4.23 ± 0.09 a
Methyl digallate 3.33 ± 0.44 a 27.80 ± 4.88 c 10.47 ± 0.50 b ND
Digalloylquinic acid 0.22 ± 0.00 a 76.48 ± 0.55 d 1.18 ± 0.10 b 2.22 ± 0.02 c
Gallotannins
Trigalloylglucose 0.02 ± 0.02 a 9.07 ± 0.04 d 0.85 ± 0.03 b 3.26 ± 0.05 c
Tetragalloylglucose 1.64 ± 0.02 a 14.50 ± 0.89 b 3.16 ± 0.13 a 88.37 ± 3.22 c
Penta-galloylglucose 4.13 ± 0.07 a 26.61 ± 0.91 b 3.93 ± 0.04 a 177.31 ± 2.14 c
Hexagalloylglucose 4.00 ± 0.08 a 74.46 ± 0.03 b 9.78 ± 0.25 a 63.72 ± 7.92 b
Hepta-galloylglucose 3.59 ± 0.00 a 58.26 ± 1.75 c 7.75 ± 0.15 b ND
Values with different superscripts a,b,c,d in the same row denoted significant differences according to the
Student-Newman-Keulstest at p < 0.05. ND: not detected.
The occurrence of gallotannins, hydrolyzable tannins, was also detected in mango pulp and its
by-products. Indeed, mango is recognized as one of the fruit with the major content of gallotannins [17].
Gallotannins contain gallic acid substituents esterified with glucose whose galloylation reaction
yields tri-, tetra-, penta-, hexa-, and hepta-galloylglucoses (Table 1). Gallotannins concentrations
varied according to the fraction of mango considered. Pulp and seed husk exhibited the poorest
content of gallotannis (13.37 ± 0.02 and 25.47 ± 0.52 mg/100 gdry matter, respectively) meanwhile peel
and seed presented considerably higher total amounts (182.90 ± 3.62 and 332.66 ± 13.32 mg/100
gdry matter, respectively). Mango peel was characterized by the significant concentrations of tri- and
hepta-galloylglucose compared to the rest of the samples. On the other hand, mango seed resulted to
be especially rich in tetra- and penta-galloylglucose. The high concentration of penta-galloylglucose in
mango seed (177.31 ± 2.41mg/100 gdry matter), which also was observed by other authors [13], should be
noted due to its multiple functional properties such as antioxidant, anti-cancer, anti-viral, anti-microbial,
anti-inflammatory, and anti-diabetic activities [18]. However, from a functional point of view, it should
be taken into account that seed content in penta-galloylglucose could decrease drastically during the
maturation process, as has been recently reported for mango pulp [19].
A large number of phenolic acid compounds derived from vanillic acid, hydroxybenzoic acid,
coumaric acid, ferulic acid, and sinapic acid were also found in mango pulp and its by-products
(Table 2). The most abundantly occurring phenolic acid derivative was vanillic acid glucoside whose
concentrations in mango peel and seed were significant higher than in mango pulp and seed husk.
Based on the results, mango peel exhibited the major amounts of phenolic acid derivative compounds.
However, only the presence of vanillic acid glucoside, p-hydroxybenzoic acid glucoside, and ferulic
acid hexoside on mango seed was confirmed. Therefore, phenolic acid derivative compounds seemed
to not play an important role in the antiplatelet activity of mango seed extract.
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Table 2. Mean concentration of gallic acid derivative compounds from different parts of Keitt mango
variety at optimum maturation stage expressed as mg/100 gdry matter.
COMPOUNDS
PULP PEEL SEED HUSK SEED
MEAN SD MEAN SD MEAN SD MEAN SD
Vanillic acid glucoside 3.90 ± 0.19 a 16.68 ± 0.42 c 7.94 ± 0.36 b 15.91 ± 0.77 c
p-Hydroxybenzoic acid glucoside 7.65 ± 0.52 c 7.27 ± 0.20 c 2.58 ± 0.07 a 6.06 ± 0.18 b
Dihydroxybenzoic acid glucoside 0.45 ± 0.00 a 0.36 ± 0.01 a 0.75 ± 0.07 b ND
Hydroxybenzoyl galloyl glucoside 0.26 ± 0.00 b 0.26 ± 0.01 b 0.07 ± 0.01 a ND
Coumaric acid glucoside 0.07 ± 0.00 a 0.52 ± 0.01 c 0.29 ± 0.02 b ND
Coumaroyl galloyl glucoside 0.29 ± 0.02 a,b 19.69 ± 0.27 c 0.61 ± 0.00 b ND
Ferulic acid hexoside 2.50 ± 0.09 b 1.81 ± 0.01 a 1.91 ± 0.01 a 2.91 ± 0.22 c
Sinapic acid hexoside 0.32 ± 0.00 a 0.97 ± 0.00 b ND ND
Sinapic acid hexoside-pentoside 7.73 ± 0.08 b 14.16 ± 0.07 c 6.96 ± 0.05 a ND
Dihydro sinapic acid hexoside-pentoside 3.57 ± 0.07 a 4.90 ± 0.08 b 3.53 ± 0.09 a ND
Values with different superscripts a,b,c in the same row denoted significant differences according to the
Student-Newman-Keuls test at p < 0.05. ND: not detected.
Other compounds of different nature and structure were also detected in mango samples (Table 3).
Regarding ellagic acid and catechin, pulp and seed husk presented the lowest values, while seed was
the mango fraction with the highest amount of ellagic acid (7.46 ± 0.54 mg/100 gdry matter). The quantity
of ellagic acid in mango seed extract had been reported from 3 to 156 mg equivalents of gallic
acid per 100 g depending on the extraction method [20]. Several studies have proven the strong
radical-scavenging activity of ellagic acid, even at very low concentrations [21,22]. Quercetin was
also detected in glycosides, with the most common forms found being quercetin glucoside, quercetin
galactoside, quercetin xyloside, and quercetin arabinopyranoside (Table 3). These flavonols were
almost exclusively found in mango peel, which was in good agreement with findings reported by other
authors [13,23]. Only small quantities of quercetin glucoside were detected in seed husk and seed.
Table 3. Mean concentration of ellagic acid, flavonols, xanthones, and benzophenones from different
parts of Keitt mango variety at optimum maturation stage expressed as mg/100 gdry matter.
COMPOUNDS
PULP PEEL SEED HUSK SEED
MEAN SD MEAN SD MEAN SD MEAN SD
Ellagic acid 0.02 ± 0.00 a 1.35 ± 0.03 b 0.56 ± 0.04 a 7.46 ± 0.54 c
Catechin 0.49 ± 0.01 a 12.18 ± 0.78 c 1.17 ± 0.26 a 9.97 ± 0.71 b
Quercetin glucoside ND 21.28 ± 0.63 c 0.21 ± 0.05 a 1.39 ± 0.14 b
Quercetin galactoside ND 10.91 ± 0.45 b 0.02 ± 0.00 a ND
Quercetin xyloside ND 2.83 ± 0.25 a ND ND
Quercetin arabinopyranoside ND 2.94 ± 0.20 a ND ND
Rhamnetin hexoside ND 2.37 ± 0.05 a ND ND
7-O-galloyltricetilflavan ND 2.91 ± 0.11 a ND 13.99 ± 0.29 b
Mangiferin ND ND 3.75 ± 0.29 a 148.12 ± 0.74 b
Maclurin C-glucoside ND ND 0.01 ± 0.01 a 11.40 ± 0.48 b
Maclurin galloyl glucoside ND 4.60 ± 0.04 b 0.84 ± 0.12 a 9.63 ± 0.04 c
Maclurin digalloyl glucoside ND 1.63 ± 0.04 a ND 6.21 ± 0.28 b
Iriflophenone glucoside ND ND ND 10.89 ± 0.28 a
Values with different superscripts a,b,c in the same row denoted significant differences according to the
Studente-Newman-Keuls test at p < 0.05. ND: not detected.
On the other hand, the phenolic fraction of mango seed was characterized by the highest
concentrations of 7-O-galloyltricetilflavan, mangiferin, and benzophenones such as maclurin
glucoside, maclurin galloyl glucoside, maclurin digalloyl glucoside, and iriflophenone glucoside
(Table 3). Among them, the most striking differences were those found on mangiferin content
(1,3,6,7-tetrahydroxyxanthone-C2-β-D-glucoside). Mango seed showed the highest quantities of
mangiferin (148 ± 0.74 mg/100 gdry matter). Only small amounts of mangiferin were found in seed
husk, while its occurrence was not detectable in pulp and peel. These results were in good agreement
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with those reported in bibliography, which also regarded mango seed as the part of mango with the
highest mangiferin content [13,24]. Furthermore, the content of mangiferin in mango seed appeared
to be influenced by the cultivar, as cv.Keitt presented major quantities of mangiferin in comparison
with other varieties such as Osteen or Sensación [24]. The abundance of mangiferin in mango seed
should be noted since mangiferin has been highlighted as a multi-target bioactive compound due to its
health-endorsing properties. Indeed, several therapeutic and cosmetic applications have been recently
attributed to mangiferin due to its antioxidative, antiaging, antidiabetic, anti-tumor, neuropropetective,
cardiovascular, immunomodulatory and hepatoprotective effects, among others [25,26]. Consequently,
the anti-platelet aggregation activity of mangiferin (1.0 mg mL−1) on human platelet whose aggregation
was induced by ADP (4 µM) was also estimated. Results showed that mangiferin has an important
anti-platelet effect, exhibiting 31% inhibition (Figure 3). However, it has been demonstrated that
for the same concentration, the antiplatelet aggregation activity increased more than two fold in
mango seed. Therefore, although mangiferin showed a considerably bioactive effect, the antiplatelet
activity of mango seed could also be explained by the action of other phenolic compounds and their
possible synergistic interactions, or even by the presence of other compounds with reported bioactivity
such as carbohydrates [27]. The percentage of carbohydrates reported in mango seed (64.24%) was
considerably higher than that found in mango peel (31.24%) [28], which could have had an influence on
the antiplatelet activity observed by mango seed. On the other hand, results compiled in bibliography
also pointed out seed as the mango by-product with the highest antioxidant activity (28.92–32.61 g
of Trolox equivalents per 100 g) compared to mango peel (5.39–6.01 g of Trolox equivalent per 100 g)
evaluated by different in vitro methods [29]. Therefore, based our results and those found in other
authors, mango seed seems to be an excellent source of phytochemicals with functional properties.
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Figure 3. Antiplatelet aggregation activity results of mango seed extract and mangiferin at 1.0 mg/mL
against ADP agonist (4 µM) expressed as mean value of inhibition percentages (n = 6). Data was
analyzed using ANOVA of one factor. Post hoc analyses were conducted by Tukey’s test. *** denotes
significant differences compared to the negative control (absence of extract) at p = 0.001; ns denotes no
statistical differences.
4. Conclusions
Mango seed was revealed as the fraction of the fruit with the most significant dose-dependent
anti-platelet aggregation activity (inhibition percentage: 72%), compared to other mango by-products
and the edible fraction. The chemical differences in phenolic composition found among different
fractions of mango seemed to explain its bioactivity. Although angiferin appeared to play a key
role in this bioactivity, the antiplatelet effect of mango seed extract was not entirely explained by
Antioxidants 2019, 8, 517 9 of 11
its action. Other compounds such as gallic acid, methylgallate and galloylquinic acid, tetra- and
penta-galloylglucose, ellagic acid, 7-o-galloyltricetilflavan, iriflophenone glucoside, and maclurin
C-glucoside and its derivatives were pointed out as contributors to antiplatelet aggregation activity.
However, a comprehensive study of their individual antiplatelet properties should be addressed in
further research.
Taken together, these results highlighted the use of mango seed as a promising natural co-product
with antiplatelet properties, which can be used as a pharmaceutical drug or as a functional food
ingredient with therapeutic applications against platelet aggregation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/11/517/s1,
Table S1: Spectral and chromatographic data regarding to the bioactive compounds identified in mango and its
by-products by HPLC-DAD-q-TOF-MS.
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